‘Diabetic Neuropathy Treatment Market Set To Grow To Over $4.3bn By 2018’ Says Visiongain Report

31 July 2018
Pharma

Visiongain has launched a new pharma report Diabetic Neuropathy Treatment: World Market 2018-2028: Analysis and Forecasts by Disorder (Peripheral, Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies

Diabetic neuropathy is a chronic disorder characterised by nerve damage caused due to prolonged elevated levels of blood glucose. Diabetic neuropathy may be caused by both type 1 and type 2 diabetes. It affects sensory, motor and autonomic nerves of the body. Treatment of diabetic neuropathy depends upon the type of nerve damage.

The lead analyst of the report commented “Increase in the incidence of diabetes is the major factor increasing the size of the diabetic neuropathy treatment market. Rises in obesity, unhealthy diets, consumption of alcohol & smoking and sedentary lifestyles, along with an ageing population are all factors that in combination are anticipated to increase the diabetic neuropathy market. Furthermore, approvals for drugs associated with diabetic neuropathy control by the FDA is anticipated to further escalate the market growth.
However, side effects of diabetic neuropathy drugs and rising cost of drugs is estimated to hinder the market growth. Ongoing, research and development associated with diabetic neuropathy treatment is anticipated to create new opportunities in the forecast period.
Leading companies featured in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc., Lupin Limited, Glenmark Pharmaceuticals Limited, Depomed, Inc., Astellas Pharma Inc., and Pfizer Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

Read

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

Read

Visiongain Publishes Respiratory Drug Delivery Technologies Market Report 2022-2032

The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.

15 June 2022

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

14 June 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever